title: Why treat anemia in the preoperative period of joint replacement surgery with erythropoietin? IMPACT consults. Proceedings of the 2nd Annual Cleveland Clinic Perioperative Medicine Summit.
abstract: Treatment of anemia in the perioperative period of major orthopedic surgery decreases the need for blood transfusion and improves perioperative outcomes. Use of epoetin alfa in this setting is FDA-approved and provides significant benefit to qualified and carefully chosen patients.
authors.affiliation: Section of Hospital Medicine, Department of General Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. kumara@ccf.org
authors.forename: Ajay
authors.initials: A
authors.lastname: Kumar
authors.forename: Vesselin
authors.initials: V
authors.lastname: Dimov
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D019643:Arthroplasty, Replacement; D001803:Blood Transfusion; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care; D011994:Recombinant Proteins; D012306:Risk
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa